QTX6255 / Quanta Therap - LARVOL DELTA

Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress (The Manila Times) - "Advancing QTX6255, potential best-in-class pan-KRAS inhibitor, on track for IND filing in 4Q26...The QTX3034-cetuximab combination demonstrated anti-tumor activity in patients with refractory CRC; 25% overall response rate (ORR) with up to 5.5 months duration, 75% disease control rate (DCR) and 5 partial responses (2 unconfirmed); High disease control rates and deep responses were achieved with QTX3034 and cetuximab combined with FOLFOX chemotherapy in a primarily chemo-refractory patient population; 50% ORR with ongoing responses up to 3.9 months duration, 90% DCR, 4 partial responses (1 unconfirmed) and 1 complete response in a chemotherapy-naïve patient....Clinical activity was supported by deep molecular responses, with most patients on either combination treatment regimen achieving more than 90% clearance in G12D ctDNA."

IND • P1 data • Colorectal Cancer • Solid Tumor